A grant of orphan drug status provides seven years of market exclusivity for the orphan indication after approval by the FDA, as well study design assistance, and eligibility for grant funding from the FDA during its development.
Alan Husband, group director of research for Marshall Edwards, said: “This grant of orphan drug status is a significant step in the development program for triphendiol as a multipotent anticancer agent.”